GNTbm TKI - GNT Biotech and Medicals Corporation
Alternative Names: GNTbm-TKI - GNT Biotech and Medicals CorporationLatest Information Update: 17 Nov 2025
At a glance
- Originator GNT Biotech and Medicals Corporation
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 21 Oct 2025 Preclinical trials in Solid tumours in Taiwan (PO)
- 17 Oct 2025 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 50th European Society for Medical Oncology Congress (ESMO-2025)
- 14 Oct 2025 Pharmacodynamics data from a preclinical trial in Solid tumours released by GNT Biotech and Medicals Corporation